Guizhou Bailing Group Pharmaceutical (002424.SZ) subsidiary's Tangning Tongluo Cream approved for clinical trials.

Guizhou Bailing Group Pharmaceutical (002424.SZ) announced that recently, its wholly-owned subsidiary Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. ("Bailing Yuxiu") received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The company's clinical trial application for Tangning Tongluo Cream complies with the relevant requirements for drug registration. On the basis of further improving the clinical trial protocol, it has been approved to conduct clinical trials for the treatment of diabetic foot ulcers. The receipt by Bailing Yuxiu, a wholly-owned subsidiary of the company, of the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving Tangning Tongluo Cream to conduct clinical trials for the treatment of diabetic foot ulcers, is an important milestone R&D achievement in the company's Tangning Tongluo pipeline. It is conducive to advancing the company's layout of a "oral + topical" treatment system for diabetic complications. The approval of clinical trials for Tangning Tongluo Cream will not have a significant impact on the company's current performance for the time being.